Evidence map›Paper›PMID 40936697›Full record

ArticleFrontiers in oncology2025

ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity.

Sofia Morazzo, Soraia Fernandes, Marina Fortea, Helena Skálová, Daniel Pereira-Sousa, Marco Cassani, Kamila Vrzalová, Filip Kafka, Jan Vrbský, Mathilde Soulez and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sofia MorazzoInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Soraia FernandesInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Marina ForteaEuropean Molecular Biology Laboratory, Barcelona, Spain.
Helena SkálováInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Daniel Pereira-SousaInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Marco CassaniInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Kamila VrzalováInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Filip KafkaInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Jan VrbskýInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Mathilde SoulezInstitute for Research in Immunology and Cancer, Montreal, QC, Canada.
Sylvain MelocheInstitute for Research in Immunology and Cancer, Montreal, QC, Canada.
Ole Morten-SeternesDepartment of Pharmacy, UIT The Arctic University of Norway, Tromso, Norway.
Veronika BosákováInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Jaeyoung ShinAtoGen Co., Ltd., Daejeon, Republic of Korea.
Jan FričInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.
Kristina HaaseEuropean Molecular Biology Laboratory, Barcelona, Spain.
Giancarlo ForteInternational Clinical Research Center (ICRC), St Anne's University Hospital, Brno, Czechia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, in which epithelial-to-mesenchymal transition (EMT) plasticity is required for successful metastasis. ERK3 has been implicated in promoting breast cancer migration and invasion, but the mechanisms remain elusive. Here, we investigated ERK3 expression across patient-derived datasets and explored its role in promoting EMT plasticity using different 2D and 3D

Indexed as

collective migrationepithelial-mesenchymal plasticity (EMP)epithelial-to-mesenchymal transition (EMT)Extracellular signal-regulated kinase 3 (ERK3)mitogen-activated protein kinase 6 (MAPK6)Triple-negative breast cancer (TNBC)

Identifiers

PMID40936697
PMCPMC12420279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.